NCT06298682 Characterization of Exosomes Platelets-released
| NCT ID | NCT06298682 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centro Cardiologico Monzino |
| Condition | Platelet Thrombus |
| Study Type | OBSERVATIONAL |
| Enrollment | 175 participants |
| Start Date | 2021-07-08 |
| Primary Completion | 2026-07-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 175 participants in total. It began in 2021-07-08 with a primary completion date of 2026-07-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Extracellular vesicles (EVs) play a key role in cell-to-cell communication. They are small vesicles that contain rich molecular cargo. Recently, they have been proposed as biomarkers for clinical diagnostics. EVs include three classes: small EVs (exosomes), large EVs (microparticles), and apoptotic bodies. Platelet-derived EVs (PEVs) are the most abundant class in human blood and can actively participate in numerous physiological and pathological processes. The information about the role of platelet exosomes in cardiovascular disease and the effect of antiplatelet agents on their release and content is very limited.
Eligibility Criteria
Inclusion Criteria: * subjects without known pathologies Exclusion Criteria: * individuals with gastrointestinal diseases, * individuals with history of hepatic diseases, * individuals with history of urogenital diseases, * individuals with history of hematological diseases, * individuals with history of immunological diseases, * individuals with history of renal diseases, * individuals with history of metabolic diseases * individuals with history of respiratory diseases * individuals with history of cancer * individuals with history of cardiovascular disease * individuals having permanent organ damage * individuals with major trauma in the last 6 months prior to enrollment * individuals with surgery in the last 6 months prior to enrollment * individuals taking medication in the 15 days prior to enrolment.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06298682 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, up to 60 Years, studying Platelet Thrombus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06298682 currently recruiting?
Yes, NCT06298682 is actively recruiting participants. Contact the research team at silvia.barbieri@ccfm.it for enrollment information.
Where is the NCT06298682 trial being conducted?
This trial is being conducted at Milan, Italy.
Who is sponsoring the NCT06298682 clinical trial?
NCT06298682 is sponsored by Centro Cardiologico Monzino. The trial plans to enroll 175 participants.